Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Retained Earnings (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Retained Earnings for 3 consecutive years, with -$330.5 million as the latest value for Q4 2025.

  • For Q4 2025, Retained Earnings fell 256139.53% year-over-year to -$330.5 million; the TTM value through Dec 2025 reached -$330.5 million, down 256139.53%, while the annual FY2025 figure was -$330.5 million, 256139.53% down from the prior year.
  • Retained Earnings hit -$330.5 million in Q4 2025 for Artiva Biotherapeutics, down from $87000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $338000.0 in Q3 2024 and bottomed at -$330.5 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$97.3 million, with a median of -$63500.0 recorded in 2024.
  • Year-over-year, Retained Earnings skyrocketed 99.93% in 2024 and then crashed 256139.53% in 2025.
  • Artiva Biotherapeutics' Retained Earnings stood at -$181.3 million in 2023, then surged by 99.93% to -$129000.0 in 2024, then plummeted by 256139.53% to -$330.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$330.5 million, $87000.0, and $2000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.